New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
The prevalence of Neuroendocrine Tumors has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Neuroendocrine tumors and the rising awareness regarding the disease and its advancement in treatment among the population is helping to drive the market. The companies developing the potential therapies in the last stage of development include ITM Solucin, Pfizer, Boehringer Ingelheim, and several others.
DelveInsight’s 'Neuroendocrine Tumors Pipeline Insight 2023' report provides comprehensive global coverage of pipeline neuroendocrine tumors therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the neuroendocrine tumors pipeline domain.
Key Takeaways from the Neuroendocrine Tumors Pipeline Report
- DelveInsight’s neuroendocrine tumors pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for neuroendocrine tumors treatment.
- Key neuroendocrine tumors companies such as Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others are evaluating new neuroendocrine tumors drugs to improve the treatment landscape.
- Promising neuroendocrine tumors pipeline therapies such as 177Lu-edotreotide PRRT, Axitinib, AlphaMedix, 64Cu MeCOSar Octreotate, Foslinanib, Belzutifan, Actinium-225 Dotate, Pelcitoclax, Debio 4126 controlled release, BI 764532, RO7616789, Satoreotide trizoxetan, rSIFN-co, CAM-2029, RRx-001, Lenvatinib, PEN-221, Belzutifan, Tirapazamine, Sunitinib, NP-101, PT217, FF-10850, Lurbinectedin, 23ME-00610, BLU-667, CC-223, Paltusotine, TAK 580, PV-10, NV 103, and others are under different phases of neuroendocrine tumors clinical trials.
- In March 2023, RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labeled somatostatin analog therapy.
- In March 2023, NUCLIDIUM announced that the Neuroendocrine Tumors Research Foundation (“NETRF”) has selected the company and its collaboration partner the University Hospital Basel (Universitätsspital Basel, “USB”) as recipients of its Investigator Award. The grant will support the initiation and execution of Phase 1 clinical trial with TraceNETTM, a novel copper-based radio diagnostic for detecting neuroendocrine tumors (NET).
- In March 2023, PharmaLogic Holdings Corp. announced the signature of a Master Services Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned subsidiary of Perspective Therapeutics, Inc., for the development and production of theranostic candidates VMT-01 and VMT-α-NET. Radiopharmaceuticals are currently in development for the diagnosis and treatment of metastatic melanoma and neuroendocrine tumors (NETs), respectively.
- In January 2023, Viewpoint Molecular Targeting®, Inc., announced the first dosing of two neuroendocrine tumor patients with therapeutic intent. VMT-α-NET, which is being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, was administered to the patients in early December. The dosed patients were diagnosed with confirmed-advanced somatostatin-expressing neuroendocrine tumors (NETs).
- In October 2022, the FDA granted a fast-track designation to 177Lu-edotreotide (ITM-11) for use as a potential therapeutic option in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to an announcement from ITM Isotype Technologies Munich SE. ITM-11 is comprised of the octreotide-derived somatostatin analog edreotide (Dotatoc) and no-carrier lutetium-177 chloride, which is a beta-emitting therapeutic radioisotope.
- In November 2022, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights(1) to POINT’s PNT2002 and PNT2003 product candidates.
Request a sample and discover the recent advances in neuroendocrine tumors treatment drugs @ Neuroendocrine Tumors Pipeline Report
The neuroendocrine tumors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage neuroendocrine tumors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the neuroendocrine tumors clinical trial landscape.
Neuroendocrine Tumors Overview
Neuroendocrine tumors are rare types that develop in specialized cells known as neuroendocrine cells. Neuroendocrine cells contain characteristics that are similar to nerve cells and hormone-producing cells. Neuroendocrine tumors can arise everywhere in the body, although most occur in the lungs, appendix, small intestine, rectum, and pancreas. Neuroendocrine tumors form when neuroendocrine cells’ DNA changes. The neuroendocrine tumors symptoms include pain from a growing tumor, a growing lump you can feel under the skin, loss of appetite/weight loss, losing weight without trying, skin flushing, diarrhea, and others.
A thorough physical examination and a battery of specialized tests are used to make neuroendocrine tumors diagnosis. Ultrasound, CT, and MRI imaging examinations aid in the diagnosis of tumor images. Images for neuroendocrine tumors are sometimes obtained utilizing positron emission tomography (PET) using a radioactive tracer injected into a vein. A biopsy can also be performed. Neuroendocrine tumor treatment is determined by the type of tumor, its location, and its severity. Chemotherapy, targeted medication therapy, and hormone therapy are all neuroendocrine tumors treatment possibilities. The tumor can be removed surgically.
Find out more about neuroendocrine tumors treatment drugs @ Drugs for Neuroendocrine Tumors Treatment
A snapshot of the Neuroendocrine Tumors Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| 177Lu-edotreotide PRRT | ITM Solucin | Phase III | Ionizing radiation emitters | Intravenous |
| Axitinib | Pfizer | Phase II/III | Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists | Oral |
| AlphaMedix | Radiomedix, Inc./Orano Med LLC | Phase II | Ionising radiation emitters | Intravenous |
| 64Cu MeCOSar Octreotate | Clarity Pharmaceuticals | Phase II | Positron-emission tomography enhancers | Intravenous |
| Foslinanib | TaiRx | Phase II | Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors | Oral |
| Belzutifan | Merck Sharp & Dohme LLC | Phase II | Endothelial PAS domain-containing protein 1 inhibitors | Oral |
| Actinium-225 Dotate | RayzeBio | Phase I/II | Ionising radiation emitters | NA |
| Pelcitoclax | Ascentage Pharma | Phase I | Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors | Intravenous |
| Debio 4126 controlled release | Debiopharm | Phase I | Growth hormone-releasing hormone inhibitors | Intramuscular |
| BI 764532 | Boehringer Ingelheim | Phase I | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Intravenous |
| RO7616789 | Roche | Phase I | Undefined mechanism | Intravenous |
Learn more about the emerging neuroendocrine tumors pipeline therapies @ Neuroendocrine Tumors Clinical Trials
Neuroendocrine Tumors Therapeutics Assessment
The neuroendocrine tumors pipeline report proffers an integral view of the neuroendocrine tumors emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Neuroendocrine Tumors Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Angiogenesis inhibitors, Platelet-derived growth factor beta receptor antagonists, Proto oncogene protein c-kit inhibitors, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, Ionising radiation emitters, Bcl-X protein inhibitors, Proto-oncogene protein c-bcl-2 inhibitors, Positron-emission tomography enhancers, Apoptosis stimulants, Growth inhibitors, Growth hormone-releasing hormone inhibitors, Somatostatin receptor agonists, Endothelial PAS domain-containing protein 1 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants
- Key Neuroendocrine Tumors Companies: Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
- Key Neuroendocrine Tumors Pipeline Therapies: 177Lu-edotreotide PRRT, Axitinib, AlphaMedix, 64Cu MeCOSar Octreotate, Foslinanib, Belzutifan, Actinium-225 Dotate, Pelcitoclax, Debio 4126 controlled release, BI 764532, RO7616789, Satoreotide trizoxetan, rSIFN-co, CAM-2029, RRx-001, Lenvatinib, PEN-221, Belzutifan, Tirapazamine, Sunitinib, NP-101, PT217, FF-10850, Lurbinectedin, 23ME-00610, BLU-667, CC-223, Paltusotine, TAK 580, PV-10, NV 103, and others.
Dive deep into rich insights for new drugs for neuroendocrine tumors treatment, visit @ Neuroendocrine Tumors Drugs
Table of Contents
| 1. | Neuroendocrine Tumors Pipeline Report Introduction |
| 2. | Neuroendocrine Tumors Pipeline Report Executive Summary |
| 3. | Neuroendocrine Tumors Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Neuroendocrine Tumors Clinical Trial Therapeutics |
| 6. | Neuroendocrine Tumors Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Neuroendocrine Tumors Pipeline: Late-Stage Products (Phase III) |
| 7.1. | 177Lu-edotreotide PRRT: ITM Solucin |
| 8. | Neuroendocrine Tumors Pipeline: Mid-Stage Products (Phase II) |
| 8.1. | Belzutifan: Merck Sharp & Dohme LLC |
| 9. | Neuroendocrine Tumors Pipeline: Early-Stage Products (Phase I) |
| 9.1. | BI 764532: Boehringer Ingelheim |
| 10. | Neuroendocrine Tumors Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Neuroendocrine Tumors Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Neuroendocrine Tumors Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the neuroendocrine tumors pipeline therapeutics, reach out @ Neuroendocrine Tumors Treatment Drugs
Related Reports
Neuroendocrine Tumors Epidemiology
Neuroendocrine Tumors Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the neuroendocrine tumors epidemiology trends.
Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies, including Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Provectus Biopharmaceuticals, Vivace Therapeutics, among others.
Gastroenteropancreatic Neuroendocrine Tumors Market
Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroenteropancreatic neuroendocrine tumors companies, including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, among others.
Gastroenteropancreatic Neuroendocrine Tumors Pipeline
Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastroenteropancreatic neuroendocrine tumors companies, including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, among others.
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the gastroenteropancreatic neuroendocrine tumors epidemiology trends.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
